Prior to Novartis, Dr Brennan worked at Fidelity Biosciences and prior to that worked in business development for several early-stage biotechnology companies.
Jeffrey Hatfield, CEO of Vitae Pharmaceuticals, said: “The life sciences industry is tracking on a path of tremendous change, centered around a rapidly increasing link – even co-dependency – between large pharma and biotech.
“With Vitae’s multiple clinical programs, expanding pipeline and highly productive and capital efficient discovery engine, making Vitae a more outward-facing organisation became the next critical step in our evolution. I am especially pleased to gain the help of someone as talented and successful as Christine for this important role.”
Dr Brennan said: “I am delighted to be a part of the successful team at Vitae and I look forward to helping the company and its partners – both current and future – achieve their goals together via strategically aligned and value accelerating collaborations.”